Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „vemurafenib“
Suchtreffer
Begriffe & Kennungen
Cotellic · 4.5 · There is no evidence of any clinically significant drug-drug interaction between cobimetinib and vemurafenib i
Eintrag öffnenCotellic · 4.5 · Vemurafenib
Eintrag öffnenCotellic · 4.8 · 11 Table 3 Adverse drug reactions (ADRs) in patients treated with Cotellic in combination with vemurafenib in
Eintrag öffnenCotellic · 4.8 · ADR frequencies are based upon the safety analysis of patients treated with cobimetinib plus vemurafenib with
Eintrag öffnenCotellic · 4.8 · Bleeding events have been reported more frequently in the Cotellic plus vemurafenib arm than in the placebo pl
Eintrag öffnenCotellic · 4.8 · Changes in reported Cobimetinib plus Placebo plus vemurafenib laboratory data vemurafenib (n = 246) (n = 247)
Eintrag öffnenCotellic · 4.8 · Cutaneous squamous cell carcinoma has been reported with a lower frequency in the Cotellic plus vemurafenib ar
Eintrag öffnenCotellic · 4.8 · In the Phase III study with Cotellic in combination with vemurafenib in patients with unresectable or metastat
Eintrag öffnenCotellic · 4.8 · Photosensitivity has been observed with a higher frequency in the Cotellic plus vemurafenib arm vs placebo plu
Eintrag öffnenCotellic · 4.8 · Please refer to the vemurafenib SmPC for complete descriptions of all undesirable effects associated with vemu
Eintrag öffnenCotellic · 4.8 · The safety of Cotellic in combination with vemurafenib has also been evaluated in 129 patients with advanced B
Eintrag öffnenCotellic · 4.8 · The safety of Cotellic in combination with vemurafenib has been evaluated in 247 patients with advanced BRAF V
Eintrag öffnenVemurafenib
Eintrag öffnenZelboraf · 4.5 · 8 Caution should be exercised when dosing vemurafenib concurrently with P-gp substrates (e.g. aliskiren, ambri
Eintrag öffnenZelboraf · 4.5 · A clinical drug interaction study demonstrated that multiple oral doses of vemurafenib (960 mg twice daily) in
Eintrag öffnenZelboraf · 4.5 · Co-administration of itraconazole, a strong CYP3A4/Pgp inhibitor, increased steady state vemurafenib AUC by ap
Eintrag öffnenZelboraf · 4.5 · Co-administration of vemurafenib resulted in an 18% increase in AUC of S-warfarin (CYP2C9 substrate). Exercise
Eintrag öffnenZelboraf · 4.5 · Concomitant use of vemurafenib with agents metabolized by CYP1A2 with narrow therapeutic windows (e.g. agomela
Eintrag öffnenZelboraf · 4.5 · Concomitant use of vemurafenib with agents metabolized by CYP3A4 with narrow therapeutic windows is not recomm
Eintrag öffnenZelboraf · 4.5 · Due to the long half-life of vemurafenib, the full inhibitory effect of vemurafenib on a concomitant medicinal
Eintrag öffnen